ADC Therapeutics

Biotechnology ResearchVaud, Switzerland201-500 Employees

ADC Therapeutics is a commercial-stage global pioneer in the field of antibody drug conjugates (ADCs). 
 
Our goal is to be a leading ADC company that transforms the lives of those impacted by cancer. We are a pioneer in the ADC field with specialized capabilities unique to ADCs from clinical to manufacturing and commercialization with a proven track record that includes an approved and marketed product. 

Our CD19-directed ADC ZYNLONTA® (loncastuximab tesirine-lpyl) received accelerated approval by the FDA and conditional approval from the European Commission for the treatment of relapsed or refractory diffuse large B-cell lymphoma after two or more lines of systemic therapy. ZYNLONTA is also in development in combination with other agents and in earlier lines of therapy. In addition to ZYNLONTA, ADC Therapeutics is leveraging its expertise to advance IND-enabling activities for a next-generation PSMA-targeting ADC.

Founded in 2011, ADC Therapeutics is based in Lausanne, Switzerland, with operations in New Jersey. Our highly skilled global team is committed to confronting cancer with the full potential of our science and transforming the treatment paradigm for patients with cancer.

For more information, please visit https://www.adctherapeutics.com/.

Sign up for free to view info

Email Format Employee directory